纳米材料在健康和疾病中的免疫毒性:在易感人群中识别免疫调节剂的当前挑战和新方法。

IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Sabine Hofer, Norbert Hofstätter, Benjamin Punz, Ingrid Hasenkopf, Litty Johnson, Martin Himly
{"title":"纳米材料在健康和疾病中的免疫毒性:在易感人群中识别免疫调节剂的当前挑战和新方法。","authors":"Sabine Hofer,&nbsp;Norbert Hofstätter,&nbsp;Benjamin Punz,&nbsp;Ingrid Hasenkopf,&nbsp;Litty Johnson,&nbsp;Martin Himly","doi":"10.1002/wnan.1804","DOIUrl":null,"url":null,"abstract":"<p><p>Nanosafety assessment has experienced an intense era of research during the past decades driven by a vivid interest of regulators, industry, and society. Toxicological assays based on in vitro cellular models have undergone an evolution from experimentation using nanoparticulate systems on singular epithelial cell models to employing advanced complex models more realistically mimicking the respective body barriers for analyzing their capacity to alter the immune state of exposed individuals. During this phase, a number of lessons were learned. We have thus arrived at a state where the next chapters have to be opened, pursuing the following objectives: (1) to elucidate underlying mechanisms, (2) to address effects on vulnerable groups, (3) to test material mixtures, and (4) to use realistic doses on (5) sophisticated models. Moreover, data reproducibility has become a significant demand. In this context, we studied the emerging concept of adverse outcome pathways (AOPs) from the perspective of immune activation and modulation resulting in pro-inflammatory versus tolerogenic responses. When considering the interaction of nanomaterials with biological systems, protein corona formation represents the relevant molecular initiating event (e.g., by potential alterations of nanomaterial-adsorbed proteins). Using this as an example, we illustrate how integrated experimental-computational workflows combining in vitro assays with in silico models aid in data enrichment and upon comprehensive ontology-annotated (meta)data upload to online repositories assure FAIRness (Findability, Accessibility, Interoperability, Reusability). Such digital twinning may, in future, assist in early-stage decision-making during therapeutic development, and hence, promote safe-by-design innovation in nanomedicine. Moreover, it may, in combination with in silico-based exposure-relevant dose-finding, serve for risk monitoring in particularly loaded areas, for example, workplaces, taking into account pre-existing health conditions. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.</p>","PeriodicalId":23697,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"14 6","pages":"e1804"},"PeriodicalIF":6.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787548/pdf/","citationCount":"0","resultStr":"{\"title\":\"Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations.\",\"authors\":\"Sabine Hofer,&nbsp;Norbert Hofstätter,&nbsp;Benjamin Punz,&nbsp;Ingrid Hasenkopf,&nbsp;Litty Johnson,&nbsp;Martin Himly\",\"doi\":\"10.1002/wnan.1804\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nanosafety assessment has experienced an intense era of research during the past decades driven by a vivid interest of regulators, industry, and society. Toxicological assays based on in vitro cellular models have undergone an evolution from experimentation using nanoparticulate systems on singular epithelial cell models to employing advanced complex models more realistically mimicking the respective body barriers for analyzing their capacity to alter the immune state of exposed individuals. During this phase, a number of lessons were learned. We have thus arrived at a state where the next chapters have to be opened, pursuing the following objectives: (1) to elucidate underlying mechanisms, (2) to address effects on vulnerable groups, (3) to test material mixtures, and (4) to use realistic doses on (5) sophisticated models. Moreover, data reproducibility has become a significant demand. In this context, we studied the emerging concept of adverse outcome pathways (AOPs) from the perspective of immune activation and modulation resulting in pro-inflammatory versus tolerogenic responses. When considering the interaction of nanomaterials with biological systems, protein corona formation represents the relevant molecular initiating event (e.g., by potential alterations of nanomaterial-adsorbed proteins). Using this as an example, we illustrate how integrated experimental-computational workflows combining in vitro assays with in silico models aid in data enrichment and upon comprehensive ontology-annotated (meta)data upload to online repositories assure FAIRness (Findability, Accessibility, Interoperability, Reusability). Such digital twinning may, in future, assist in early-stage decision-making during therapeutic development, and hence, promote safe-by-design innovation in nanomedicine. Moreover, it may, in combination with in silico-based exposure-relevant dose-finding, serve for risk monitoring in particularly loaded areas, for example, workplaces, taking into account pre-existing health conditions. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.</p>\",\"PeriodicalId\":23697,\"journal\":{\"name\":\"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology\",\"volume\":\"14 6\",\"pages\":\"e1804\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787548/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/wnan.1804\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wnan.1804","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

在过去的几十年里,由于监管机构、工业界和社会的强烈兴趣,纳米安全评估经历了一个激烈的研究时代。基于体外细胞模型的毒理学分析经历了从在单一上皮细胞模型上使用纳米颗粒系统的实验到采用更逼真地模拟各自身体屏障的先进复杂模型来分析其改变暴露个体免疫状态的能力的演变。在这一阶段,我们吸取了一些教训。因此,我们已经到达了一个必须开启下一章的状态,追求以下目标:(1)阐明潜在的机制,(2)解决对弱势群体的影响,(3)测试材料混合物,(4)在(5)复杂的模型上使用实际剂量。此外,数据再现性已成为一个重要的需求。在此背景下,我们从免疫激活和调节导致促炎与耐受性反应的角度研究了不良结局途径(AOPs)的新兴概念。当考虑到纳米材料与生物系统的相互作用时,蛋白质电晕的形成代表了相关的分子起始事件(例如,通过纳米材料吸附蛋白质的潜在改变)。以此为例,我们说明了将体外分析与计算机模型相结合的集成实验计算工作流如何帮助数据丰富,并在全面的本体注释(元)数据上传到在线存储库时确保公平性(可查找性、可访问性、互操作性、可重用性)。未来,这种数字配对可能有助于治疗开发过程中的早期决策,从而促进纳米医学的设计安全创新。此外,在考虑到先前存在的健康状况的情况下,它可与硅基接触相关剂量测定相结合,用于特别负荷区域(例如工作场所)的风险监测。本文分类如下:纳米医学毒理学和监管问题>纳米材料毒理学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations.

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations.

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations.

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations.

Nanosafety assessment has experienced an intense era of research during the past decades driven by a vivid interest of regulators, industry, and society. Toxicological assays based on in vitro cellular models have undergone an evolution from experimentation using nanoparticulate systems on singular epithelial cell models to employing advanced complex models more realistically mimicking the respective body barriers for analyzing their capacity to alter the immune state of exposed individuals. During this phase, a number of lessons were learned. We have thus arrived at a state where the next chapters have to be opened, pursuing the following objectives: (1) to elucidate underlying mechanisms, (2) to address effects on vulnerable groups, (3) to test material mixtures, and (4) to use realistic doses on (5) sophisticated models. Moreover, data reproducibility has become a significant demand. In this context, we studied the emerging concept of adverse outcome pathways (AOPs) from the perspective of immune activation and modulation resulting in pro-inflammatory versus tolerogenic responses. When considering the interaction of nanomaterials with biological systems, protein corona formation represents the relevant molecular initiating event (e.g., by potential alterations of nanomaterial-adsorbed proteins). Using this as an example, we illustrate how integrated experimental-computational workflows combining in vitro assays with in silico models aid in data enrichment and upon comprehensive ontology-annotated (meta)data upload to online repositories assure FAIRness (Findability, Accessibility, Interoperability, Reusability). Such digital twinning may, in future, assist in early-stage decision-making during therapeutic development, and hence, promote safe-by-design innovation in nanomedicine. Moreover, it may, in combination with in silico-based exposure-relevant dose-finding, serve for risk monitoring in particularly loaded areas, for example, workplaces, taking into account pre-existing health conditions. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology NANOSCIENCE & NANOTECHNOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
16.60
自引率
2.30%
发文量
93
期刊介绍: Nanotechnology stands as one of the pivotal scientific domains of the twenty-first century, recognized universally for its transformative potential. Within the biomedical realm, nanotechnology finds crucial applications in nanobiotechnology and nanomedicine, highlighted as one of seven emerging research areas under the NIH Roadmap for Medical Research. The advancement of this field hinges upon collaborative efforts across diverse disciplines, including clinicians, biomedical engineers, materials scientists, applied physicists, and toxicologists. Recognizing the imperative for a high-caliber interdisciplinary review platform, WIREs Nanomedicine and Nanobiotechnology emerges to fulfill this critical need. Our topical coverage spans a wide spectrum, encompassing areas such as toxicology and regulatory issues, implantable materials and surgical technologies, diagnostic tools, nanotechnology approaches to biology, therapeutic approaches and drug discovery, and biology-inspired nanomaterials. Join us in exploring the frontiers of nanotechnology and its profound impact on biomedical research and healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信